ERBB2 and cancer: Possible causes for our patients’ below-average overall survival may be the poorer quality of care provided in terms of dose calculation and application for different chemotherapeutic agents, lack of HER2 status testing and hence treatment, stereotactic planning and application of radiation, lack of a solid follow-up program for cancer patients, very poor patient compliance both to treatment and to follow-up, and finally inadequate general supportive care for cancer patients, compared with Western standards.